Vilsbøll T, et al. - In patients grouped by sex, age (< 65 years, ≥ 65 years), and diabetes duration (<10 years, ≥10 years), researchers studied the impact of insulin degludec/liraglutide fixed-ratio combination (IDegLira) vs comparators on cardiovascular (CV) risk markers from DUAL II (vs insulin degludec), DUAL V (vs insulin glargine 100 units/mL), and DUAL VII (vs basal–bolus therapy). According to findings from this post hoc analysis, in comparison with basal insulin or basal-bolus therapy after 26 weeks of treatment, IDegLira was related to a general improvement in CV risk markers.